PER-003-06已完成未知
A RANDOMIZED, INTERNATIONAL, DOUBLE-BLIND (WITH INTERNAL BLIND) STUDY CONTROLLED WITH GARDISIL TM OF VACCINE RANGE OCTAVALENT OF PARTICLES TO VIRUS L1 (VLP) AGAINST HUMAN PAPILOMAVIRUS (HPV) (TYPES 6,11,18,31,45,52 AND 58) ADMINISTERED TO WOMEN BETWEEN 16 AND 23 YEARS OF AGE
MERCK & CO.INC.,0 个研究点目标入组 0 人开始时间: 2006年3月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The participant is between 16 years and 0 days and 23 years and 364 days on the day of randomization.
- •2. The participant fully understands the study procedures, agrees to participate in the study and has given written informed consent.
- •3. The participant is considered to be in good physical health condition.
- •4. The participant has had a history of 0 to 4 sexual partners during her life.
- •5. The participant has refrained from using vaginal shower / wash and using medication or vaginal preparations during the 2 days prior to the Day 1 visit.
- •6. The participant has abstained from sexual activity for 2 days prior to the Day 1 visit.
- •7. From the first day of the last menstrual period of the participant until Day 1, the participant has not had sexual intercourse with males or has had sex with males and has used contraceptive methods without failures.
排除标准
- •1. The participant has a history of an abnormal Pap test or an abnormal cervical biopsy result.
- •2. The participant has never had a history of an abnormal Pap test.
- •3. The participant has a history of recent or ongoing alcohol abuse or other drug abuse.
- •4. The participant has a history of severe allergic reaction that requires medical intervention.
- •5. The participant has a known allergy to any component of the vaccine, including aluminum, yeast or BENZONASE ™.
- •6. The participant is currently immunocompromised or has been diagnosed with a congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune condition.
- •7. The participant had a splenectomy.
- •8. The participant is receiving or has received immunosuppressive therapies in the year prior to enrollment.
- •9. The participant has received any immunoglobulin product or blood product within 3 months prior to the Day 1 vaccination, or is planning to receive any such product during Day 1 through Month 7 of the study.
- •10. The participant has received non-replication vaccines within 14 days prior to the Day 1 vaccination or has received replication vaccines within 21 days prior to the Day 1 vaccination.
- •11. The participant has thrombocytopenia or other coagulatory disorder that would contraindicate intramuscular injections.
- •12. The participant is currently enrolled in clinical studies of research agents or studies that involve the collection of cervical samples.
- •13. The participant has a history of participating in a clinical trial of HPV vaccine and has received an active agent or placebo.
- •14. The participant has a history of any disease or condition that may confuse the results of the study or pose an additional risk to the participant.
- •15. The participant plans a permanent relocation of the area prior to the completion of the study or absences for an extended period of time when the study visits would need to be scheduled.
- •16. The participant has had fever within the 24-hour period prior to the Day 1 vaccination.
- •17. The participant is pregnant.
- •18. The participant has clinical evidence of macroscopic purulent cervicitis.
- •19. The participant is in menstrual period.
- •20. The participant has a history of or clinical evidence in the pelvic examination of Day 1 of external genital lesions related to HPV, external genital cancer, external genital lesions of unknown etiology.
- •21. The participant does not have an intact cervix or has more than one cervix.
研究者
相似试验
已完成
不适用
A RANDOMIZED, INTERNATIONAL, DOUBLE-BLINDED (WITH IN-HOUSE BLINDING), CONTROLLED WITH GARDASIL™, DOSE-RANGING, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY STUDY OF A MULTIVALENT HUMAN PAPILLOMAVIRUS (HPV) L1 VIRUS-LIKE PARTICLE (VLP) VACCINE ADMINISTERED TO 16- TO 26-YEAR-OLD WOME-B977 Papillomavirus as the cause of diseases classified to other chaptersPapillomavirus as the cause of diseases classified to other chaptersB977PER-090-13MERCK SHARP & DOHME PERU S.R.L.,230
未知
不适用
AN INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF RINDOPEPIMUTC/GM-CSF WITH ADJUVANT TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED, SURGICALLY RESECTED, EGFRVIII-POSITIVE GLIOBLASTOMAPER-049-12Celldex Therapeutics, Inc.,1
未知
不适用
A MULTI-NATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-PERIOD CROSSOVER STUDY WITH GSK 573719 AS MONOTHERAPY IN ADULT SUBJECTS WITH ASTHMAPER-045-12GlaxoSmithKline,87
已完成
不适用
INTERNATIONAL RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF KIACTATM IN PREVENTING RENAL FUNCTION DECLINE IN PATIENTS WITH AA AMYLOIDOSISPER-012-11AUVEN THERAPEUTICS (A.T Development Switzeriand SARL).,17
已完成
不适用
A RANDOMIZED, MULTINATIONAL, DOUBLE-BLIND, PLACEBO-CONTROLLED AND PARALLEL-GROUP ACTIVE COMPARATOR STUDY TO EXAMINE THE SAFETY, TOLERABILITY AND EFFICACY OF ROFECOXIB OF 50 AND 25 MG FOR THE ACUTE TREATMENT OF MIGRAINE-G43G43PER-062-01MERCK SHARP & DOHME PERU S.R.L.,